| Amount | Holding |
|---|---|
| 4.94% | Vertex Pharmaceuticals Inc |
| 4.81% | UnitedHealth Group Inc |
| 4.03% | DexCom Inc |
| 3.62% | Eli Lilly and Co |
| 3.07% | Bristol-Myers Squibb Company |
| 2.96% | Gilead Sciences Inc |
| 2.93% | Tolero Cdr/Rec |
| 2.87% | AbbVie Inc |
| 2.79% | Sarepta Therapeutics Inc |
| 2.74% | Danaher Corp |
| 2.60% | Thermo Fisher Scientific Inc |
| 2.60% | Merck & Co Inc |
| 2.52% | Abbott Laboratories |
| 2.48% | AstraZeneca PLC ADR |
| 2.44% | Biogen Inc |
| 2.24% | Regeneron Pharmaceuticals Inc |
| 2.23% | Novartis AG ADR |
| 1.92% | Insulet Corp |
| 1.90% | Teladoc Health Inc |
| 1.88% | Cigna Corp |
| 1.87% | eHealth Inc |
| 1.71% | Allergan PLC |
| 1.59% | Humana Inc |
| 1.59% | Zoetis Inc Class A |
| 1.44% | GW Pharmaceuticals PLC ADR |
Expense Ratio Rating
1 /10
Expense Rating
0 /10
Market Score
3 /10
Category Score
0 /10
Market Size
3 /10
$AHSCX Alternatives
14%
FI Score
- ahscx
- Mutual Fund
- Sector Equity
- Healthcare
Alger Health Sciences Fund Class C
Expenses: 1.89% (Better than 0% of similar funds)
This is a bad choice for a Healthcare Sector Equity fund. See why ยป